Drug intelligence / Profile preview

ZK093

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical
Modality: Small Molecules

Overview

ZK093 is a preclinical-stage drug candidate being developed by Lee's Pharmaceutical for the treatment of depression. Described as a new generation antidepressant, it is a small molecule compound currently undergoing preclinical evaluation to establish its safety and efficacy profile. As of 2024, specific details regarding its molecular target and mechanism of action have not been publicly disclosed by the sponsor, though it is positioned within their psychiatry pipeline as a novel therapeutic for depressive disorders.

Beyond the preview

Go deeper on ZK093.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK093.

Explore the full profile